Breaking News, Trials & Filings

ProBioGen’s Avian AGE1.CR Cell Line Platform in Clinical Trials

Production of the first ever batch of MVA for a clinical trial using a cell line

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Complex biologics development and manufacturing specialist ProBioGen recently announced that an investigational vaccine against Ebola virus disease, produced on its proprietary, continuous muscovy duck AGE1.CR.pIX cell line, has proceeded into clinical trials at the Jenner Institute, Oxford University, UK. The vaccine candidate, a modified vaccinia Ankara (MVA) Ebola Zaire vaccine (MVA EBOZ) was produced by Emergent BioSolutions at a 200 liter scale to supply the Phase 1 clinical trial. “Prod...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters